The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome

Harris, S.L. and Jones, D.W. and Gallimore, M.J. and Nicholls, P.J. and Winter, M. (2005) The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome. Journal of Thrombosis & Haemostasis, 3 (5). pp. 969-975. ISSN 1538-7933 . (The full text of this publication is not available from this repository)

The full text of this publication is not available from this repository. (Contact us about this Publication)
Official URL
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=...

Abstract

Phospholipid binding proteins, including factor XII (FXII), are known to be targeted by antiphospholipid antibodies (aPA). Factor XII antibodies (FXIIab) have been described in some patients with the antiphospholipid syndrome (APS) and have been shown to lead to reduced levels of FXII. The antigenic binding site(s) and the pathophysiological effects of FXIIab are unknown. In an attempt to elucidate the binding site of these antibodies, immobilized plasma kallikrein was used to cleave FXII into its 52-kDa heavy-chain (HCFXII) and 28-kDa light-chain (LCFXII) components. Plasma samples from 12 female patients with definite APS and FXIIab were investigated for the presence of antibodies to FXII, HCFXII and LCFXII. All but one patient's plasma reacted to FXII, HCFXII and LCFXII in a similar manner. One patient gave markedly reduced positivity to HCFXII and LCFXII, suggesting that the FXIIab in this patient had a higher affinity for the intact FXII molecule. To further investigate the antigenic binding site(s) of FXII, 150 biotinylated peptides of the known FXII sequence were synthesized using a Multipin(TM) peptide synthesis procedure. The IgG and IgM fractions of the 12 patients' plasma were purified by affinity chromatography. The synthesized peptides were captured on streptavidin plates and individual patients' purified FXIIab assayed against the peptides in a modified enzyme-linked immunosorbent assay (ELISA). Two regions were identified as possible antigenic binding site(s) for FXIIab: one in the growth factor domain and the other in the catalytic domain.

Item Type: Article
Additional information: 1538-7933 (Print) Journal Article
Uncontrolled keywords: Amino Acid Sequence Antibodies/*chemistry Antigens/chemistry Antiphospholipid Syndrome/*immunology/metabolism Binding Sites Biotinylation Catalytic Domain Electrophoresis, Polyacrylamide Gel Enzyme-Linked Immunosorbent Assay Factor XII/*chemistry/*immunology Humans Immunoglobulin G/chemistry Immunoglobulin M/chemistry Macromolecular Substances/chemistry Molecular Sequence Data Multiprotein Complexes/chemistry Peptides/chemistry Prekallikrein/chemistry Protein Conformation Reproducibility of Results Silver Staining
Subjects: Q Science
Divisions: Faculties > Science Technology and Medical Studies > School of Biosciences > Biomedical Research Group
Depositing User: D Wynne Jones
Date Deposited: 04 Sep 2008 17:38
Last Modified: 21 May 2011 00:31
Resource URI: http://kar.kent.ac.uk/id/eprint/5588 (The current URI for this page, for reference purposes)
  • Depositors only (login required):